<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04597450</url>
  </required_header>
  <id_info>
    <org_study_id>19364A</org_study_id>
    <nct_id>NCT04597450</nct_id>
  </id_info>
  <brief_title>Lu AG06466 in Participants With Post Traumatic Stress Disorder (PTSD)</brief_title>
  <official_title>Interventional, Randomized, Double-Blind, Crossover, Placebo-Controlled, Exploratory Study Investigating the Effects of Lu AG06466 on BOLD fMRI Signals and Sleep Parameters in Patients With PTSD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of Lu AG06466 after multiple doses of&#xD;
      30 milligrams (mg) in participants with PTSD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The crossover study consists of two treatment periods of 15 days duration. On Day -1 or Day 1&#xD;
      of Treatment Period 1, eligible participants will be randomized (1:1) to a sequence of&#xD;
      treatments (either Lu AG06466-placebo or placebo-Lu AG06466) with 15 participants are planned&#xD;
      per sequence. Each treatment period will be separated by a washout period of ≥7 and ≤14 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2020</start_date>
  <completion_date type="Anticipated">January 8, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Functional Magnetic Resonance Imaging (fMRI) Data: Mean Blood Oxygen Level Dependent (BOLD) Percent Signal Change During Facial Affect Recognition Task</measure>
    <time_frame>Day 15</time_frame>
    <description>fMRI parameter estimates (β-contrasts) will be extracted per participant/treatment period from task-related regions of interest (ROIs) under task-specific contrast, Facial Affect Recognition Task</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional Magnetic Resonance Imaging (fMRI) Data: Mean Blood Oxygen Level Dependent (BOLD) Percent Signal Change During Threat Processing Task</measure>
    <time_frame>Day 15</time_frame>
    <description>fMRI parameter estimates (β-contrasts) will be extracted per participant/treatment period from task-related regions of interest (ROIs) under task-specific contrast, Threat Processing Task</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional Magnetic Resonance Imaging (fMRI) Data: Mean Blood Oxygen Level Dependent (BOLD) Percent Signal Change During Card Guessing Task</measure>
    <time_frame>Day 15</time_frame>
    <description>fMRI parameter estimates (β-contrasts) will be extracted per participant/treatment period from task-related regions of interest (ROIs) under task-specific contrast, Card Guessing Task</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skin Conductance Response (SCR) During fMRI Tasks</measure>
    <time_frame>Day 15</time_frame>
    <description>SCR in micro-Siemens</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skin Conductance Response (SCR) During the Threat Processing Task</measure>
    <time_frame>Day 14</time_frame>
    <description>SCR in micro-Siemens</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Behavioural Measures During fMRI Tasks</measure>
    <time_frame>Day 15</time_frame>
    <description>Behavioural Response: behavioural measures rated on a 3-point scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Behavioural Measures During the Threat Processing Task</measure>
    <time_frame>Day 14</time_frame>
    <description>Behavioural Response: behavioural measures rated on a 3-point scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sleep, Polysomnography (PSG) Parameters: Total Sleep Time (TST)</measure>
    <time_frame>Day 12-13</time_frame>
    <description>TST in minutes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sleep, Polysomnography (PSG) Parameters: Sleep Efficiency (SE)</measure>
    <time_frame>Day 12-13</time_frame>
    <description>SE in percent</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sleep, Polysomnography (PSG) Parameters: Wake-Time After Sleep-Onset (WASO)</measure>
    <time_frame>Day 12-13</time_frame>
    <description>WASO in minutes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sleep, Polysomnography (PSG) Parameters: Sleep Onset Latency (SOL)</measure>
    <time_frame>Day 12-13</time_frame>
    <description>SOL in minutes</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>PTSD</condition>
  <arm_group>
    <arm_group_label>Lu AG06466</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AG06466</intervention_name>
    <description>Lu AG06466 - 30 mg/day, capsules, orally, once daily, one capsule will be taken daily for 15 days per treatment period</description>
    <arm_group_label>Lu AG06466</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo - capsules, orally, once daily, one capsule will be taken daily for 15 days per treatment period</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The participant has a body mass index (BMI) of ≥18.5 and ≤35 kilograms (kg)/square&#xD;
             meter (m^2).&#xD;
&#xD;
          -  The participant has PTSD, diagnosed according to Diagnostic and Statistical Manual&#xD;
             Diploma in Social Medicine-5 (DSM-5), and confirmed by the Mini International&#xD;
             Neuropsychiatric Interview (MINI).&#xD;
&#xD;
          -  The participant has a Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total score&#xD;
             ≥28 at screening and baseline.&#xD;
&#xD;
          -  The participant has alterations in arousal and reactivity, confirmed on CAPS-5.&#xD;
&#xD;
          -  The participant has ongoing sleep disturbances, confirmed on CAPS-5.&#xD;
&#xD;
          -  The participant is willing to discontinue all prohibited medications during the study&#xD;
             and to complete a washout of psychotropic medication during the washout period.&#xD;
&#xD;
          -  The participant does not have any magnetic resonance imaging (MRI) contraindications.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The index traumatic event that led to development of PTSD took place &gt;15 years or &lt;6&#xD;
             months before screening.&#xD;
&#xD;
        Other inclusion and exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@Lundbeck.com</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <phone>+45 36301311</phone>
    <email>LundbeckClinicalTrials@Lundbeck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Collaborative NeuroScience Network LLC</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 2, 2020</study_first_submitted>
  <study_first_submitted_qc>October 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

